Feature Article

Personalized Medicine in Psoriasis: Patient Stratification Is Key Step Forward


Although truly personalized medicine is not yet feasible in psoriasis treatment, a stratified approach to selection of therapies may offer some of the benefits of personalized medicine.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News


Carboxytherapy for Patients With Chronic Localized Plaque Psoriasis

By February 19, 2018

The investigators recommend increasing the number of carboxytherapy sessions and adding maintenance sessions to patients' treatment regimens.


Some Psoriasis Treatments May Exacerbate Inflammatory Bowel Disease

By February 15, 2018

Although treatment with etanercept, secukinumab, brodalumab, and ixekizumab has been shown to be effective among patients with psoriasis and psoriatic arthritis, use of these agents may actually exacerbate or induce symptoms of inflammatory bowel disease.


Scalp Psoriasis Data Added to Secukinumab Labeling

By February 14, 2018

The FDA has approved updated labeling for Cosentyx to include data regarding the use of secukinumab in the treatment of moderate to severe plaque psoriasis.


Factors That Affect Quality of Life in Psoriasis

By February 12, 2018

Appearance-related factors seem to weigh most heavily on adolescent patients with psoriasis.


Apremilast Safe, Effective After Switch From Etanercept in Psoriasis

By February 09, 2018

At Week 16, significantly higher proportions of apremilast-treated patients vs placebo-treated patients achieved PASI-75.


Psoriatic Arthritis Symptoms Improved With Apremilast Monotherapy

By February 07, 2018

Patients with psoriatic arthritis who were taking and were naive to biologic medications experienced symptom relief with apremilast as early as 2 weeks into therapy.


Ixekizumab Has Sustained Efficacy in Biologic-Naive Active Psoriatic Arthritis

By February 05, 2018

Treatment with ixekizumab demonstrated sustained efficacy and a favorable safety profile in patients with active psoriatic arthritis previously naive to biologic disease-modifying antirheumatic drugs.


Less Frequent Clinical Visits May Actually Benefit Patients With Psoriasis

February 05, 2018

For patients with psoriasis, a patient-initiated care consultation intervention may offer clinical benefits compared with routine care.


Medication Nonadherence in Psoriasis Influenced by Beliefs, Habits

By January 25, 2018

Beliefs and habits regarding medical treatment and therapy are modifiable factors that may help to improve treatment response.


Psoriasis Remission After HCV Treatment: Case Report

January 19, 2018

The patient's skin lesions started to resolve gradually soon after initiation of ledipasvir-sofosbuvir therapy.

Sign up for Newsletters